Xenetic Biosciences (NASDAQ:XBIO) Posts Quarterly Earnings Results, Misses Estimates By $0.14 EPS

Xenetic Biosciences (NASDAQ:XBIOGet Free Report) announced its earnings results on Tuesday. The company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.14), Zacks reports. The business had revenue of $0.61 million during the quarter, compared to the consensus estimate of $0.75 million. Xenetic Biosciences had a negative return on equity of 47.21% and a negative net margin of 161.63%.

Xenetic Biosciences Stock Performance

Shares of XBIO traded down $0.05 during mid-day trading on Thursday, reaching $3.60. The company had a trading volume of 10,227 shares, compared to its average volume of 11,218. Xenetic Biosciences has a 52 week low of $2.78 and a 52 week high of $5.20. The company has a market capitalization of $5.55 million, a price-to-earnings ratio of -1.47 and a beta of 2.25. The firm has a 50-day moving average price of $3.89 and a 200 day moving average price of $3.93.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “neutral” rating on shares of Xenetic Biosciences in a research report on Tuesday, August 20th.

Check Out Our Latest Analysis on XBIO

About Xenetic Biosciences

(Get Free Report)

Xenetic Biosciences, Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.

Read More

Earnings History for Xenetic Biosciences (NASDAQ:XBIO)

Receive News & Ratings for Xenetic Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenetic Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.